Navigation Links
ESA Names James P. Whelan Vice President, Sales & Marketing, Clinical Diagnostic Products

CHELMSFORD, Mass., June 9 /PRNewswire/ -- ESA Biosciences, a Magellan Biosciences company and leader in dedicated systems to screen children for lead poisoning, announced that James P. Whelan has joined the company as vice president of sales and marketing for ESA's clinical-diagnostics business. Mr. Whelan comes to ESA from Laboratory Corporation of America, where he was most recently vice president of managed care for LabCorp's esoteric business. Previously, he was vice president of marketing and business development for the company, responsible for marketing LabCorp's $3 billion diagnostics business to physicians, hospitals, and managed care.

"ESA's clinical-diagnostics business has grown significantly since we introduced the CLIA-waived LeadCare(R) II system in the fall of 2006," said Magellan's President and Chief Executive Officer, Dr. Robert J. Rosenthal. "We are delighted to have Jim Whelan on board as we expand the reach of our existing products into new markets, extend our point-of-care platform to other analytes, and add to our portfolio of diagnostic products. Our focus remains providing clinicians with the fast and reliable results they need to make good treatment decisions and improve health outcomes for their patients. I am confident that with Jim's proven skills, leadership capabilities, and extensive experience with physicians, managed care plans, and distribution management, we will continue our ascent to a leadership position as a world-class diagnostics company."

"This is indeed an exciting time in ESA's corporate history," said Mr. Whelan. "Blood-lead-testing volumes are on the rise as reports of lead-tainted products and lead in the environment have encouraged physicians, parents, politicians, and other community stakeholders to focus on the serious health effects of lead exposure. Where it has been adopted as a screening device to identify children with elevated blood-lead levels, clinicians tell us that LeadCare II is an unqualified success: more at-risk children are being screened, clinicians are able to provide immediate treatment when necessary, parental education is more effective, and compliance rates for follow-up appointments rise. However, barriers to widespread implementation of the point-of-care system still exist in many states. I look forward to working across the spectrum of stakeholders to help ensure that all at-risk children have access to point-of-care screening, and that pediatricians and community health clinics have access to reimbursement."

Prior to his tenure at LabCorp, Mr. Whelan worked for 20 years at Fisher Scientific International in various capacities to significantly improve the company's distribution management and sales-channel development. Most recently, he was senior vice president for business development, e-commerce, and was an active member of the core executive operating team that was responsible for company structure, brand architecture, marketing, and operating plan development. Mr. Whelan has a bachelor's degree in biology from the University of Bridgeport in Connecticut.

About CLIA-waived LeadCare II

The LeadCare II system makes lead testing easy, delivering quantitative blood-lead results with only two drops of blood in just three minutes. Far simpler to administer than traditional blood-lead tests, the device can be used with capillary or venous sample, can be combined with other routine waived blood tests, and saves administrative time spent on paper work, tracking, and follow-up. Most important, it improves health outcomes -- children with elevated blood-lead levels can receive immediate intervention, rather than waiting days or weeks for results. In the US, LeadCare tests are typically reimbursable (CPT code 83655) and cost-effective -- allowing health systems to focus resources on those truly at risk. Parents concerned that their children may have been exposed to lead should ask their pediatrician for this simple test. The system is also being used successfully in industrial-hygiene programs, to test adults who might be exposed to lead as part of their work.

For more information, call 1 (800) 305-0197, or e-mail For links to important toy-recall information, lead-poisoning resources, and articles, visit

About ESA (

ESA Biosciences, Inc. enables answers to pressing applications challenges by applying its expertise in specialty detection and electrochemistry, combined with components, kits, and reagents, for analytical laboratories, commercial diagnostics laboratories, and the clinical point-of-care setting. ESA is a wholly owned subsidiary of Magellan Biosciences, Inc.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Robb Morse

SOURCE Magellan Biosciences
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. VA Names 13 to Rural Health Advisory Committee
2. MonoSol Rx Names Vincent Viviani Senior Vice President, Manufacturing and Operations
3. Flashpoint Launches Flashlight Interactive, Names Kristen Goelz Head of New Division
4. Natural Solutions Names 45 Must-Have Foods for Healthy Weight Loss
5. The International Rett Syndrome Foundation Names Antony Horton Ph.D. Chief Scientific Officer
6. NJHA Names Fred J. Jacobs General Counsel
7. AMA Foundation Names Minority Scholars Award Recipients
8. The Gladney Center for Adoption Names Mark L. Melson as Executive Vice President/Chief Development Officer
9. Ohio Association of Health Plans Names Pinnacle Awards to Programs That Improve Health Care for Ohioans
10. North Castle Partners Names Dennis Lee of Octane Fitness CEO of the Year
11. Emdeon Business Services Names Miriam Paramore Senior Vice President of Corporate Strategy
Post Your Comments:
(Date:11/25/2015)... ... 25, 2015 , ... Students and parents have something to be thankful for ... Real Impact awards. California Casualty is proud to support the contest designed ... and reckless driving, the number one killer of young drivers. , Almost 1,000 ...
(Date:11/24/2015)... PA (PRWEB) , ... November 24, 2015 , ... ... now certified to offer their patients the many benefits of the revolutionary BIOLASE ... the sharp cutting and scraping tools traditionally used by a dentist in ...
(Date:11/24/2015)... ... November 24, 2015 , ... Young patients with a wide ... Angela Wolfman and Dr. Kedar S. Lele, who are pediatric dentists in Tucson, ... fillings, the WaterLase iPlus 2.0™ system causes minimal discomfort and bleeding to the patient ...
(Date:11/24/2015)... , ... November 24, 2015 , ... In an ... restrictions and variables that determine which patients are or are not eligible for bariatric ... have a BMI over 40, are more than 100 pounds overweight, or have a ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... national leaders when it comes to several aspects of orthopedic care. They have ... replacements, orthopedic surgeries and general orthopedic care. , Becker's Hospital Review selected ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Thanks to ... Dignity Health St. Mary,s Medical Center,s Sister Diane Grassilli ... breast imaging capabilities in San Francisco ... an anonymous friend, stepped forward with a gift of ... for Breast Digital Mammography with Tomosynthesis and Whole Breast ...
(Date:11/24/2015)... TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ - ... NASDAQ: EPIX ) announced today that the first ... study of EPI-506 as a treatment for metastatic castration-resistant ... and Canada.  --> ... --> In the Phase 1/2 clinical trial, ESSA ...
(Date:11/24/2015)... --> --> According to ... Type (Bone Graft, Bine Graft Substitute, Platelet Rich Plasma, BMAC), ... Fusion), End User, and Geography - Global Forecast to 2020", ... Billion in 2014 and is expected to reach $2.4 Billion ... period of 2015 to 2020. Browse 55 market ...
Breaking Medicine Technology: